Since Cytodyn shareholders don't get to see real clinical trial data it must be hard to understand Gilead's impressive results.
Gilead spends the money to have clinical trials that can actually show statistically significant results and is developing an injectable and an oral for HIV combo, mono and PrEP all at once. Cytodyn can't seem to figure out how to do a trial that can meet an endpoint. That's why they are where they are -- failed GvHD, Failed ALL three CoV trials. Can't even file an BLA because the CEO is too busy trying to pump the stock for his insider trading.
Gilead produced a novel technology -- capsid inhibitor that prevents HIV from replicating regardless of type. It prevents it early so it is an ideal mode of action for PrEP (trials in process already). They have an injectable and an oral. They have a Twice a year dosing schedule for the ultimate in convenience. They are already in trials for an HIV mono.
That's a lot of drug technology. The HIV combo had efficacy 81-95% -- better than LL. Safety=placebo, like reportedly LL is. The oral is a single daily dose that can be taken with the HAART regimen for real convenience.
Gilead expects this will take over for HIV treatment market.
Gilead also has three different HIV cures in development too.
Looks like Gilead is getting a lot for it's HIV R&D budget. Will clearly steamroll LL.
News 
Market Data 
Discover 
